BioCentury
ARTICLE | Tools & Techniques

'So long, and thanks for all the drugs'

January 11, 1999 8:00 AM UTC

Even if Wall Street's interest in biotech proved mostly fickle in 1998, the reaction to EntreMed's anti-angiogenesis data in May proved what mice have known all along - human drugs work really well in rodents.

Indeed, ENMD's stupendous one-day run-up to more than $1 billion in market cap should point to the real opportunity for biotech: if all drug candidates work in mice, then everyone should concentrate on technology to transform the human immune system into the mouse version...